Antiemetic therapy options for chemotherapy-induced nausea and vomiting in breast cancer patients

Vicky TC Chan, Winnie YeoDepartment of Clinical Oncology, Faculty of Medicine, Chinese University of Hong Kong, Hong Kong SAR, ChinaAbstract: Chemotherapy-induced nausea and vomiting (CINV) continues to be one of the most distressing side effects of chemotherapy in breast cancer patients, which can...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Chan VTC, Yeo W
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2011
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/39a09043cade45fe948f079e611ca0cd
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:39a09043cade45fe948f079e611ca0cd
record_format	dspace
spelling	oai:doaj.org-article:39a09043cade45fe948f079e611ca0cd2021-12-02T02:54:56ZAntiemetic therapy options for chemotherapy-induced nausea and vomiting in breast cancer patients1179-1314https://doaj.org/article/39a09043cade45fe948f079e611ca0cd2011-11-01T00:00:00Zhttp://www.dovepress.com/antiemetic-therapy-options-for-chemotherapy-induced-nausea-and-vomitin-a8650https://doaj.org/toc/1179-1314Vicky TC Chan, Winnie YeoDepartment of Clinical Oncology, Faculty of Medicine, Chinese University of Hong Kong, Hong Kong SAR, ChinaAbstract: Chemotherapy-induced nausea and vomiting (CINV) continues to be one of the most distressing side effects of chemotherapy in breast cancer patients, which can result in poor compliance to therapy that may, in turn, affect overall survival. The extent of CINV is dependent on the emetogenic potential of the individual cytotoxic agents or regimens employed as well as certain patient factors. Advances in our understanding in the pathophysiology of CINV and the identification of risk factors have enabled the utilization of appropriate antiemetic regimens to improve the control of CINV. Most of the chemotherapy regimens used in this patient population are considered to be moderately emetogenic; 60%&ndash;90% of chemotherapeutic regimens used in breast cancer patients cause nausea and vomiting, amongst which regimens doxorubicin-cyclophosphamide (AC) combination is commonly regarded as of relatively higher emetogenicity. Currently, corticosteroids, 5-hydroxytryptamine 3 (5-HT3) receptor antagonists, and neurokinin 1 (NK-1) receptor antagonists are the three classes of antiemetic agents with the highest therapeutic index, which have been supported by data from large-scale randomized clinical trials. Treatment guidelines enable physicians to integrate the latest research data into their clinical practices. This review focuses on the three classes of antiemetic therapy options for CINV in breast cancer patients, as well as their safety and tolerability profiles. Recommendations from major guidelines/consensus including from the Multinational Association for Supportive Care in Cancer/European Society of Medical Oncology (MASCC/ESMO), the American Society of Clinical Oncology (ASCO), and the US National Comprehensive Cancer Network (NCCN), are also discussed. With the correct use of antiemetic regimens, chemotherapy-induced vomiting could be prevented in the majority of patients. However, chemotherapy-induced nausea remains an important symptom and a challenge for physicians to manage.Keywords: cytotoxics, 5-HT3 antogonist, NK-1 antagonistChan VTCYeo WDove Medical PressarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENBreast Cancer: Targets and Therapy, Vol 2011, Iss default, Pp 151-160 (2011)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Chan VTC Yeo W Antiemetic therapy options for chemotherapy-induced nausea and vomiting in breast cancer patients
description	Vicky TC Chan, Winnie YeoDepartment of Clinical Oncology, Faculty of Medicine, Chinese University of Hong Kong, Hong Kong SAR, ChinaAbstract: Chemotherapy-induced nausea and vomiting (CINV) continues to be one of the most distressing side effects of chemotherapy in breast cancer patients, which can result in poor compliance to therapy that may, in turn, affect overall survival. The extent of CINV is dependent on the emetogenic potential of the individual cytotoxic agents or regimens employed as well as certain patient factors. Advances in our understanding in the pathophysiology of CINV and the identification of risk factors have enabled the utilization of appropriate antiemetic regimens to improve the control of CINV. Most of the chemotherapy regimens used in this patient population are considered to be moderately emetogenic; 60%&ndash;90% of chemotherapeutic regimens used in breast cancer patients cause nausea and vomiting, amongst which regimens doxorubicin-cyclophosphamide (AC) combination is commonly regarded as of relatively higher emetogenicity. Currently, corticosteroids, 5-hydroxytryptamine 3 (5-HT3) receptor antagonists, and neurokinin 1 (NK-1) receptor antagonists are the three classes of antiemetic agents with the highest therapeutic index, which have been supported by data from large-scale randomized clinical trials. Treatment guidelines enable physicians to integrate the latest research data into their clinical practices. This review focuses on the three classes of antiemetic therapy options for CINV in breast cancer patients, as well as their safety and tolerability profiles. Recommendations from major guidelines/consensus including from the Multinational Association for Supportive Care in Cancer/European Society of Medical Oncology (MASCC/ESMO), the American Society of Clinical Oncology (ASCO), and the US National Comprehensive Cancer Network (NCCN), are also discussed. With the correct use of antiemetic regimens, chemotherapy-induced vomiting could be prevented in the majority of patients. However, chemotherapy-induced nausea remains an important symptom and a challenge for physicians to manage.Keywords: cytotoxics, 5-HT3 antogonist, NK-1 antagonist
format	article
author	Chan VTC Yeo W
author_facet	Chan VTC Yeo W
author_sort	Chan VTC
title	Antiemetic therapy options for chemotherapy-induced nausea and vomiting in breast cancer patients
title_short	Antiemetic therapy options for chemotherapy-induced nausea and vomiting in breast cancer patients
title_full	Antiemetic therapy options for chemotherapy-induced nausea and vomiting in breast cancer patients
title_fullStr	Antiemetic therapy options for chemotherapy-induced nausea and vomiting in breast cancer patients
title_full_unstemmed	Antiemetic therapy options for chemotherapy-induced nausea and vomiting in breast cancer patients
title_sort	antiemetic therapy options for chemotherapy-induced nausea and vomiting in breast cancer patients
publisher	Dove Medical Press
publishDate	2011
url	https://doaj.org/article/39a09043cade45fe948f079e611ca0cd
work_keys_str_mv	AT chanvtc antiemetictherapyoptionsforchemotherapyinducednauseaandvomitinginbreastcancerpatients AT yeow antiemetictherapyoptionsforchemotherapyinducednauseaandvomitinginbreastcancerpatients
_version_	1718402034793709568

Antiemetic therapy options for chemotherapy-induced nausea and vomiting in breast cancer patients

Ejemplares similares